Cantabio in the News

The Tao of Tau & Picking apart PD

The Tao of Tau & Picking apart PD

DD News Pharma Biotech and Life Science featured Cantabio's recent peer reviewed publication in ACS Chemical Neuroscience on the structural basis for the suitability of Tau as a drug target, as well as reporting on Cantabio's recently announced positive in vivo efficacy in mammalian Parkinson's disease model of a candidate from its DJ-1 targeting small molecule program
Drugging the Disorderome; Strategies for targeting intrinsically disordered proteins

Drugging the Disorderome; Strategies for targeting intrinsically disordered proteins

Cantabio's therapeutic program on Alzheimer’s and Parkinson's disease was featured as part of an article titled "Drugging the Disorderome" in the October 2017 issue of The Scientist magazine.  The article reviewed the potential for developing therapeutics for historically difficult to target intrinsically disordered proteins, the new techniques that can allow the screening for drug candidates to target them and highlighted Cantabio's expertise in this area.

Chaperoning the DJ

Chaperoning the DJ

Cover Story by Biocentury Innovations, describing how Cantabio is using an alternative approach, enhancing the function of the DJ-1 protein, rather than the more common dopamine compensation strategy. This means developing a disease-modifying therapy instead of treating only the disease's symptoms. Mentioning also our pharmacological chaperone approach in Alzheimer's targeting B-amyloid and tau.